Charles Schwab
AZN icon

Charles Schwab’s AstraZeneca AZN Stock Holding History

Charles Schwab’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.4M Buy
292,315
+30,778
+12% +$5.79M 0.01% 1176
2026
Q1 		$51.6M Buy
261,537
+50,345
+24% +$9.71M 0.01% 1130
2025
Q4 		$38.8M Buy
211,192
+29,472
+16% +$5.17M 0.01% 1315
2025
Q3 		$27.9M Buy
181,720
+37,881
+26% +$5.73M ﹤0.01% 1526
2025
Q2 		$20.1M Buy
143,839
+18,725
+15% +$2.62M ﹤0.01% 1674
2025
Q1 		$18.4M Sell
125,114
-746,927
-86% -$108M ﹤0.01% 1681
2024
Q4 		$114M Sell
872,041
-20,077
-2% -$2.81M 0.02% 588
2024
Q3 		$139M Buy
892,118
+4,415
+0.5% +$713K 0.03% 497
2024
Q2 		$138M Buy
887,703
+833,250
+1,530% +$125M 0.03% 498
2024
Q1 		$7.38M Sell
54,453
-19,173
-26% -$2.54M ﹤0.01% 2142
2023
Q4 		$9.92M Buy
73,626
+12,117
+20% +$1.58M ﹤0.01% 1992
2023
Q3 		$8.33M Buy
61,509
+43,305
+238% +$5.91M ﹤0.01% 2004
2023
Q2 		$2.61M Buy
18,204
+8,368
+85% +$1.23M ﹤0.01% 2473
2023
Q1 		$1.37M Buy
9,836
+3,608
+58% +$485K ﹤0.01% 2631
2022
Q4 		$844K Buy
+6,228
New +$781K ﹤0.01% 2829
2021
Q1 		– Sell
-18,050
Closed -$1.8M – 3491
2020
Q4 		$1.8M Sell
18,050
-104,450
-85% -$11.1M ﹤0.01% 2616
2020
Q3 		$13.4M Sell
122,500
-37,000
-23% -$4.12M 0.01% 1484
2020
Q2 		$16.9M Sell
159,500
-86,850
-35% -$8.97M 0.01% 1299
2020
Q1 		$22M Sell
246,350
-81,900
-25% -$7.71M 0.01% 950
2019
Q4 		$32.7M Sell
328,250
-91,750
-22% -$8.64M 0.02% 892
2019
Q3 		$37.4M Hold
420,000
– – 0.02% 739
2019
Q2 		$34.7M Hold
420,000
– – 0.02% 775
2019
Q1 		$34M Buy
+420,000
New +$33.1M 0.02% 773

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab's AZN Position: Q2 2026 in Review

Charles Schwab increased its AstraZeneca (AZN) stake by 12% in Q2 2026, buying an estimated $5.79M and bringing the position to 292,315 shares worth $55.4M. The position accounts for 0.01% of the portfolio, ranked #1176.

Charles Schwab first reported a position in AZN in Q1 2019 and has held it in 23 quarters since. The position peaked at $139M in Q3 2024. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Charles Schwab held 292,315 shares of AstraZeneca worth $55.4M as of Q2 2026.
  • Charles Schwab bought 30,778 AstraZeneca shares in Q2 2026, an estimated $5.79M.
  • AstraZeneca made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1176 holding.
  • Charles Schwab first reported a position in AstraZeneca in Q1 2019 and has held it in 23 quarters since.
  • Charles Schwab's AstraZeneca position peaked at $139M in Q3 2024.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.